Phenotyping young-onset atrial fibrillation patients (Young-AF)

Phenotyping young-onset atrial fibrillation patients (Young-AF) - Young-AF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37717

Enrollment

500

Registered

2012-07-31

Start date

2012-08-16

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -AF onset at age 18 years; -Written informed consent.

Exclusion criteria

Exclusion criteria: - Post-operative AF - Myocardial infarction, acute coronary syndrome 3 months before start AF.

Design outcomes

Primary

Measure	Time frame
At baseline the exact phenotypes of patients with young AF with versus without familial AF. Assessment of the phenotype includes clinical characteristics, presence of validated AF risk factors, (electro-)echocardiographic abnormalities, presence of vascular abnormalities, endothelial dysfunction and hypercoagulation.	—

Secondary

Measure	Time frame
I. At baseline differences in the prevalence of of 1) heart failure (systolic and diastolic); 2) stroke, TIA and peripheral embolism; 3) coronary artery disease including myocardial infarction, acute coronary syndrome and documented significant coronary artery disease necessitating treatment; 4) diabetes mellitus; 5) hypertension; 6) renal failure; 7) subclinical hyperthyroidism; 8) obesity; 9) atrial remodeling measured as increase of atrial sizes and reduction of atrial contractility; 10) biomarker profiles associated with atrial remodeling including fibrosis inflammation, dedifferentiation, etc; 11) biomarker profiles associated with vascular abnormalities, endothelial dysfunction and hyperocagulation; 12) Genes associated with phenotypes of young AF with or without a family history. II. After 1 and 5 years of follow up differences between both groups in the occurrence of 1) heart failure (systolic and diastolic); 2) stroke, TIA and peripheral embolism; 3) coronary artery disease including myocardial infarction, acute coronary syndrome and documented significant coronary artery disease necessitating treatment; 4) diabetes mellitus; 5) hypertension; 6)renal failure; 7) cardiovascular mortality; 8) bleeding; 9) severe adverse effects of antiarrhythmic drugs; 10) atrial remodeling measured as increase of atrial sizes and reduction of atrial contractility and remodeling as detected with use of body surface mapping; 11) deterioration of left ventricular systolic and diastolic function; 12) progression of AF to persistent or permanent AF; 13) association of cardiovascular morbidity and mortality with atrial remodeling; 14) biomarker profiles associated with occurrence or deterioration of atrial remodeling including fibrosis inflammation, dedifferentiation, etc; 15) biomarker profiles associated with vascular abnormalities, endothelial dysfunction and hypercoagulation; 16) Genes associated with progression of AF.	—

Measure

Time frame

I. At baseline differences in the prevalence of of 1) heart failure (systolic and diastolic); 2) stroke, TIA and peripheral embolism; 3) coronary artery disease including myocardial infarction, acute coronary syndrome and documented significant coronary artery disease necessitating treatment; 4) diabetes mellitus; 5) hypertension; 6) renal failure; 7) subclinical hyperthyroidism; 8) obesity; 9) atrial remodeling measured as increase of atrial sizes and reduction of atrial contractility; 10) biomarker profiles associated with atrial remodeling including fibrosis inflammation, dedifferentiation, etc; 11) biomarker profiles associated with vascular abnormalities, endothelial dysfunction and hyperocagulation; 12) Genes associated with phenotypes of young AF with or without a family history. II. After 1 and 5 years of follow up differences between both groups in the occurrence of 1) heart failure (systolic and diastolic); 2) stroke, TIA and peripheral embolism; 3) coronary artery disease including myocardial infarction, acute coronary syndrome and documented significant coronary artery disease necessitating treatment; 4) diabetes mellitus; 5) hypertension; 6)renal failure; 7) cardiovascular mortality; 8) bleeding; 9) severe adverse effects of antiarrhythmic drugs; 10) atrial remodeling measured as increase of atrial sizes and reduction of atrial contractility and remodeling as detected with use of body surface mapping; 11) deterioration of left ventricular systolic and diastolic function; 12) progression of AF to persistent or permanent AF; 13) association of cardiovascular morbidity and mortality with atrial remodeling; 14) biomarker profiles associated with occurrence or deterioration of atrial remodeling including fibrosis inflammation, dedifferentiation, etc; 15) biomarker profiles associated with vascular abnormalities, endothelial dysfunction and hypercoagulation; 16) Genes associated with progression of AF.

—

Countries

Netherlands

Outcome results